Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a
new wave of promising immunotherapies for the treatment of cancer. Their mechanism of …

Objective Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-
mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and …

Aims To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …

Purpose. Gastric emptying (GE) is often reported to be slower and more irregular in
premature neonates than in older children and adults. The aim of this study was to …

Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17
therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F …

Abstract Background Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-
driven asthma, the inhibition of which may improve treatment outcomes. We examined the …

The T‐optimality criterion is used in optimal design to derive designs for model selection. To
set up the method, it is required that one of the models is considered to be true. We term this …

In clinical toxicology, a better understanding of the pharmacokinetics of the drugs may be
useful in both risk assessment and formulating treatment guidelines for patients …

A new approach for calculation of sample size in pediatric clinical pharmacokinetic studies
was suggested based on desired precision for a pharmacokinetic parameter of interest. The …

Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical
modelling where the mean response in a population and the variability in response from …